243 related articles for article (PubMed ID: 17391433)
1. Glycosylation of therapeutic proteins in different production systems.
Werner RG; Kopp K; Schlueter M
Acta Paediatr; 2007 Apr; 96(455):17-22. PubMed ID: 17391433
[TBL] [Abstract][Full Text] [Related]
2. Appropriate mammalian expression systems for biopharmaceuticals.
Werner RG; Noé W; Kopp K; Schlüter M
Arzneimittelforschung; 1998 Aug; 48(8):870-80. PubMed ID: 9748718
[TBL] [Abstract][Full Text] [Related]
3. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.
Ferrara C; Brünker P; Suter T; Moser S; Püntener U; Umaña P
Biotechnol Bioeng; 2006 Apr; 93(5):851-61. PubMed ID: 16435400
[TBL] [Abstract][Full Text] [Related]
4. Glycosylation control technologies for recombinant therapeutic proteins.
Gupta SK; Shukla P
Appl Microbiol Biotechnol; 2018 Dec; 102(24):10457-10468. PubMed ID: 30334089
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in the understanding of biological implications and modulation methodologies of monoclonal antibody N-linked high mannose glycans.
Shi HH; Goudar CT
Biotechnol Bioeng; 2014 Oct; 111(10):1907-19. PubMed ID: 24975601
[TBL] [Abstract][Full Text] [Related]
6. Expression of human FcgammaRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding.
Armour KL; Smith CS; Clark MR
J Immunol Methods; 2010 Mar; 354(1-2):20-33. PubMed ID: 20138184
[TBL] [Abstract][Full Text] [Related]
7. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
8. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function.
Zhou Q; Shankara S; Roy A; Qiu H; Estes S; McVie-Wylie A; Culm-Merdek K; Park A; Pan C; Edmunds T
Biotechnol Bioeng; 2008 Feb; 99(3):652-65. PubMed ID: 17680659
[TBL] [Abstract][Full Text] [Related]
9. Cloning and characterization of a single-chain fragment of monoclonal antibody to ACE suitable for lung endothelial targeting.
Balyasnikova IV; Berestetskaya JV; Visintine DJ; Nesterovitch AB; Adamian L; Danilov SM
Microvasc Res; 2010 Dec; 80(3):355-64. PubMed ID: 20888351
[TBL] [Abstract][Full Text] [Related]
10. N-Glycosylation Design and Control of Therapeutic Monoclonal Antibodies.
Sha S; Agarabi C; Brorson K; Lee DY; Yoon S
Trends Biotechnol; 2016 Oct; 34(10):835-846. PubMed ID: 27016033
[TBL] [Abstract][Full Text] [Related]
11. A global RNA-seq-driven analysis of CHO host and production cell lines reveals distinct differential expression patterns of genes contributing to recombinant antibody glycosylation.
Könitzer JD; Müller MM; Leparc G; Pauers M; Bechmann J; Schulz P; Schaub J; Enenkel B; Hildebrandt T; Hampel M; Tolstrup AB
Biotechnol J; 2015 Sep; 10(9):1412-23. PubMed ID: 26212696
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting the expression of recombinant glycoproteins.
Devasahayam M
Indian J Med Res; 2007 Jul; 126(1):22-7. PubMed ID: 17890819
[TBL] [Abstract][Full Text] [Related]
13. Glycosylation: heterogeneity and the 3D structure of proteins.
Rudd PM; Dwek RA
Crit Rev Biochem Mol Biol; 1997; 32(1):1-100. PubMed ID: 9063619
[TBL] [Abstract][Full Text] [Related]
14. CHO cell line specific prediction and control of recombinant monoclonal antibody N-glycosylation.
Grainger RK; James DC
Biotechnol Bioeng; 2013 Nov; 110(11):2970-83. PubMed ID: 23737295
[TBL] [Abstract][Full Text] [Related]
15. Glycoengineering in CHO Cells: Advances in Systems Biology.
Tejwani V; Andersen MR; Nam JH; Sharfstein ST
Biotechnol J; 2018 Mar; 13(3):e1700234. PubMed ID: 29316325
[TBL] [Abstract][Full Text] [Related]
16. Effect of pH, temperature, and salt on the stability of Escherichia coli- and Chinese hamster ovary cell-derived IgG1 Fc.
Li CH; Narhi LO; Wen J; Dimitrova M; Wen ZQ; Li J; Pollastrini J; Nguyen X; Tsuruda T; Jiang Y
Biochemistry; 2012 Dec; 51(50):10056-65. PubMed ID: 23078371
[TBL] [Abstract][Full Text] [Related]
17. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
18. Supplementing glycosylation: A review of applying nucleotide-sugar precursors to growth medium to affect therapeutic recombinant protein glycoform distributions.
Blondeel EJM; Aucoin MG
Biotechnol Adv; 2018; 36(5):1505-1523. PubMed ID: 29913209
[TBL] [Abstract][Full Text] [Related]
19. Rapid whole monoclonal antibody analysis by mass spectrometry: An ultra scale-down study of the effect of harvesting by centrifugation on the post-translational modification profile.
Reid CQ; Tait A; Baldascini H; Mohindra A; Racher A; Bilsborough S; Smales CM; Hoare M
Biotechnol Bioeng; 2010 Sep; 107(1):85-95. PubMed ID: 20506289
[TBL] [Abstract][Full Text] [Related]
20. Identification of cell culture conditions to control N-glycosylation site-occupancy of recombinant glycoproteins expressed in CHO cells.
Gawlitzek M; Estacio M; Fürch T; Kiss R
Biotechnol Bioeng; 2009 Aug; 103(6):1164-75. PubMed ID: 19418565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
